Literature DB >> 18156458

Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality.

Anetta Undas1, Marek Kolarz, Grzegorz Kopeć, Wiesława Tracz.   

Abstract

BACKGROUND: Haemodialysis patients are at an increased risk of cardiovascular (CV) morbidity and mortality. Both end-stage renal disease (ESRD) and thromboembolic coronary events have been shown to be associated with the formation of dense fibrin clots resistant to fibrinolysis. The aim of the present study was to investigate the effect of long-term haemodialysis on clot structure/function and analyse an influence of markers of inflammation, oxidative stress and lipoprotein(a). We sought also to investigate if clot features might be related to CV events and mortality in haemodialysis patients. Subjects and methods. In 33 patients (19 males, 14 females), aged 27 to 89 years, on long-term haemodialysis and 33 age- and sex-matched apparently healthy controls, we investigated fibrin clot properties and susceptibility to lysis using recombinant tissue plasminogen activator by using permeation and turbidity assays.
RESULTS: Haemodialysis patients produced fibrin clots that had less porous structure (P < 0.0001) were less susceptible to fibrinolysis (P < 0.0001), began fibrin protofibril formation more quickly (P < 0.0001) and showed increased overall fibre thickness (P < 0.0001) compared with controls. Clot permeability and lysis time correlated with F2-isoprostanes (P < 0.01), Lp(a) (P < 0.0001) and fibrinogen (P < 0.01). None of the clot variables showed associations with the duration of haemodialysis treatment or the cause of ESRD. During a 36-month follow-up, 10 CV deaths were recorded. Mortality was associated with reduced clot permeability (P < 0.0001), prolonged lysis time (P < 0.0001), faster fibrin protofibril formation (P = 0.0004), thicker fibres (P < 0.0001) and increased fibrin clot mass (P < 0.0001).
CONCLUSIONS: Unfavourably altered clot properties can be detected in haemodialysis patients and may be associated with increased CV mortality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18156458     DOI: 10.1093/ndt/gfm884

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  18 in total

1.  Differences in coagulation between hemodialysis and peritoneal dialysis.

Authors:  Donald F Brophy; Daniel E Carl; Bassem M Mohammed; Jingmei Song; Erika J Martin; Jessica L Bostic; Todd W B Gehr
Journal:  Perit Dial Int       Date:  2013-12-01       Impact factor: 1.756

2.  Nattokinase-heparin exhibits beneficial efficacy and safety-an optimal strategy for CKD patients on hemodialysis.

Authors:  Hao Wu; Huan Wang; Wei Li; Chi Zhang; Yushan Liu; Feng Xu; Jiepeng Chen; Lili Duan; Fengjiao Zhang
Journal:  Glycoconj J       Date:  2019-02-20       Impact factor: 2.916

3.  Clot Structure: A Potent Mortality Risk Factor in Patients on Hemodialysis.

Authors:  Katharina Schuett; Anna Savvaidis; Sebastian Maxeiner; Katharina Lysaja; Vera Jankowski; Stephan H Schirmer; Nada Dimkovic; Peter Boor; Nadine Kaesler; Friedo W Dekker; Jürgen Floege; Nikolaus Marx; Georg Schlieper
Journal:  J Am Soc Nephrol       Date:  2017-01-05       Impact factor: 10.121

Review 4.  Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy.

Authors:  Constance C F M J Baaten; Jonas R Schröer; Jürgen Floege; Nikolaus Marx; Joachim Jankowski; Martin Berger; Heidi Noels
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-08       Impact factor: 8.237

Review 5.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

6.  Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.

Authors:  Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  Transl Res       Date:  2019-08-29       Impact factor: 7.012

Review 7.  Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to COVID-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability.

Authors:  Nikola Gligorijević; Dragana Stanić-Vučinić; Mirjana Radomirović; Marija Stojadinović; Urmila Khulal; Olgica Nedić; Tanja Ćirković Veličković
Journal:  Molecules       Date:  2021-05-11       Impact factor: 4.411

8.  Oxidation inhibits iron-induced blood coagulation.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Boguslaw Lipinski
Journal:  Curr Drug Targets       Date:  2013-01-01       Impact factor: 3.465

9.  Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.

Authors:  Søs Neergaard-Petersen; Ramzi Ajjan; Anne-Mette Hvas; Katharina Hess; Sanne Bøjet Larsen; Steen Dalby Kristensen; Erik Lerkevang Grove
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

10.  Aspects of platelet disturbances in haemodialysis patients.

Authors:  Marianne Schoorl; Muriel P C Grooteman; Piet C M Bartels; Menso J Nubé
Journal:  Clin Kidney J       Date:  2013-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.